Civica Takes On The Challenge Of Insulin Affordability
It Will Set Its Own Price Caps
Executive Summary
The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.
You may also be interested in...
Civica’s $27.8m New Facility Expands Virginia Drug Hub Vision
Civica has announced a further $27.8m investment to support its plans for insulin and other essential medicines. The news comes shortly after CivicaScript announced its first launch in the form of abiraterone tablets.
Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
Democratic Drug Pricing Push: Starting And Ending With Insulin?
When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.